BCP
AZN icon

Berkeley Capital Partners’s AstraZeneca AZN Stock Holding History

Berkeley Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,946
Closed -$576K – 156
2021
Q4 		$576K Sell
4,946
-274
-5% -$32.2K 0.24% 68
2021
Q3 		$627K Sell
5,220
-81
-2% -$9.43K 0.29% 57
2021
Q2 		$635K Buy
5,301
+510
+11% +$56K 0.28% 54
2021
Q1 		$476K Buy
4,791
+3
+0.1% +$302 0.23% 66
2020
Q4 		$479K Sell
4,788
-97
-2% -$10.3K 0.25% 63
2020
Q3 		$535K Sell
4,885
-852
-15% -$94.8K 0.33% 47
2020
Q2 		$607K Sell
5,737
-2,864
-33% -$296K 0.37% 45
2020
Q1 		$768K Sell
8,601
-1,487
-15% -$140K 0.52% 38
2019
Q4 		$1.01M Sell
10,088
-370
-4% -$34.8K 0.52% 43
2019
Q3 		$932K Sell
10,458
-361
-3% -$31.3K 0.49% 44
2019
Q2 		$893K Buy
10,819
+160
+2% +$12.5K 0.42% 47
2019
Q1 		$862K Sell
10,659
-1,649
-13% -$130K 0.43% 50
2018
Q4 		$935K Sell
12,308
-1,123
-8% -$87.7K 0.52% 39
2018
Q3 		$1.06M Sell
13,431
-3,043
-18% -$230K 0.6% 38
2018
Q2 		$1.16M Sell
16,474
-2,729
-14% -$196K 0.68% 31
2018
Q1 		$1.34M Sell
19,203
-3,896
-17% -$270K 0.78% 24
2017
Q4 		$1.6M Buy
23,099
+1,926
+9% +$130K 1.06% 18
2017
Q3 		$1.44M Buy
21,173
+3,851
+22% +$243K 0.96% 20
2017
Q2 		$1.18M Buy
17,322
+616
+4% +$40.2K 0.8% 24
2017
Q1 		$1.04M Sell
16,706
-6,950
-29% -$405K 0.71% 30
2016
Q4 		$1.29M Buy
23,656
+8,501
+56% +$483K 0.93% 22
2016
Q3 		$996K Sell
15,155
-2,110
-12% -$138K 0.71% 30
2016
Q2 		$1.04M Buy
+17,265
New +$1M 0.73% 28

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Berkeley Capital Partners's AZN Position: Q1 2022 in Review

Berkeley Capital Partners sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 4,946 shares — an estimated $576K sold.

Berkeley Capital Partners first reported a position in AZN in Q2 2016 and held it in 23 quarters. The position peaked at $1.6M in Q4 2017. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

  • Berkeley Capital Partners reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
  • Berkeley Capital Partners sold 4,946 AstraZeneca shares in Q1 2022, an estimated $576K.
  • Berkeley Capital Partners first reported a position in AstraZeneca in Q2 2016 and held it in 23 quarters.
  • Berkeley Capital Partners's AstraZeneca position peaked at $1.6M in Q4 2017.
  • 982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Berkeley Capital Partners's 13F filing for Q1 2022, filed 5 May 2022.